Provexis (CHIX:PXSL) EBITDA per Share: £0.00 (TTM As of Sep. 2025)


What is Provexis EBITDA per Share?

Provexis CHIX:PXSL EBITDA per Share is £0.00 as of Sep. 2025. The stock has 1 warning sign investors should review. Among 812 Drug Manufacturers companies, Provexis ranks worse than 123152.59% on this metric.

Provexis's EBITDA per Share for the six months ended in Sep. 2025 was £0.00. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 was £0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Provexis's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Provexis was 62.30% per year. The lowest was 12.60% per year. And the median was 28.15% per year.

CHIX:PXSl's 3-Year EBITDA Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Provexis's EBITDA for the six months ended in Sep. 2025 was £-0.31 Mil.

During the past 3 years, the average EBITDA Growth Rate was -14.80% per year. During the past 5 years, the average EBITDA Growth Rate was -6.40% per year. During the past 10 years, the average EBITDA Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Provexis was 43.80% per year. The lowest was -26.10% per year. And the median was 2.00% per year.


Provexis  (CHIX:PXSl) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Provexis EBITDA per Share Related Terms


Provexis EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Provexis's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provexis EBITDA per Share Chart

Provexis Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provexis Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Provexis EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Provexis's EBITDA per Share for the fiscal year that ended in Mar. 2025 is calculated as

EBITDA per Share(A: Mar. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.452/2284.370
=-0.00

Provexis's EBITDA per Share for the quarter that ended in Sep. 2025 is calculated as

EBITDA per Share(Q: Sep. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=-0.31/2345.891
=-0.00

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of £0.00 mean?
Provexis (CHIX:PXSL) has a EBITDA per Share of £0.00 as of Sep. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Provexis and its competitors. According to the industry distribution chart, Provexis ranks #999999 out of 812 companies in the Drug Manufacturers industry.
Is Provexis' EBITDA per Share too high?
Provexis' current EBITDA per Share is £0.00. Based on the distribution chart, Provexis ranks #999999 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Provexis' EBITDA per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Provexis ranks #999999 out of 812 companies for EBITDA per Share. This places Provexis in the lower half of its industry. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Provexis and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provexis's current EBITDA per Share is £0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provexis stock overvalued right now?
Provexis (CHIX:PXSL) has a current EBITDA per Share of £0.00. The current EBITDA per Share is £0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Provexis (CHIX:PXSL), the current EBITDA per Share is £0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provexis Business Description

Other Exchanges PXS:UKNZCA:Germany
Address 2 Blagrave Street, I Ford, Reading, Berkshire, GBR, RG1 1AZ
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.